SLC6A3 and Lewy body dementia: Future studies could combine cognitive performance with converging clinical and fluid biomarkers of DLB as well as structural and positron emission tomography (PET) imaging to test a predictive model built using multimodal features (e.g., by including visual hallucinations31; overlapping neuropsychiatric symptoms36; striatal dopamine transporter imaging2).